REFERENCES
- Stone TW. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 1993; 45: 309–379.
- Curzon G. Brain tryptophan. Normal and disturbed control. Adv Exp Med Biol 1996; 398: 27–34.
- Bolting NP. Chemistry and neurochemistry of the kynurenine pathway of tryptophan metabolism. Chem Soc Rev 1995; 24: 401–412.
- Heyes MP, Chen CY, Major EO, Saito K. Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochem J 1997; 326: 351–356.
- Kerr SJ, Armati PJ, Pemberton LA, Smythe G, Tattam B, Brew BJ. Kynurenine pathway inhibition reduces toxicity of HIV-infected macrophages. Neurology 1997; 49: 1671–1681.
- Tamburin M, Mostardini M, Benatti L. Kynurenine amino-transferase I (KATI) isoform gene expression in the rat brain: an in situ hybridization study. Neuroreport 1999; 10: 61–65.
- Guillemin G, Boussin F, Croitoru J, Le Grand R, Dormont D. Obtention and characterization of astrocytes and microglia from adult monkey brains. J Neurosci Res 1997; 49: 576–591.
- Kerr SJ et al. Kynurenine pathway inhibition reduces toxicity of HIV-infected macrophages. Neurology 1997; 49: 1671–1681.
- Kapoor V, Kapoor R, Chalmers J. Kynurenic acid, an endogenous glutamate antagonist, in SHR and WKY rats: possible role in central blood pressure regulation. Clin Exp Pharmacol Physiol 1994; 21: 891–896.
- Brew BJ, Wesselingh SL, Gonzales M, Heyes MP, Price RW. How HIV leads to neurological disease. Med J Aust 1996; 164: 233–234.